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Harnessing the HDAC–histone deacetylase enzymes,
inhibitors and how these can be utilised in tissue engineering
Liam Lawlor1,2 and Xuebin B. Yang 1,2
There are large knowledge gaps regarding how to control stem cells growth and differentiation. The limitations of currently
available technologies, such as growth factors and/or gene therapies has led to the search of alternatives. We explore here how a
cell’s epigenome inﬂuences determination of cell type, and potential applications in tissue engineering. A prevalent epigenetic
modiﬁcation is the acetylation of DNA core histone proteins. Acetylation levels heavily inﬂuence gene transcription. Histone
deacetylase (HDAC) enzymes can remove these acetyl groups, leading to the formation of a condensed and more transcriptionally
silenced chromatin. Histone deacetylase inhibitors (HDACis) can inhibit these enzymes, resulting in the increased acetylation of
histones, thereby affecting gene expression. There is strong evidence to suggest that HDACis can be utilised in stem cell therapies
and tissue engineering, potentially providing novel tools to control stem cell fate. This review introduces the structure/function of
HDAC enzymes and their links to different tissue types (speciﬁcally bone, cardiac, neural tissues), including the history, current
status and future perspectives of using HDACis for stem cell research and tissue engineering, with particular attention paid to how
different HDAC isoforms may be integral to this ﬁeld.
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INTRODUCTION
There is a largely unmet clinical need for the repair and
regeneration of human tissues and organs. Due to the limitations
of conventional clinical therapies, tissue engineering, a multi-
disciplinary area of research, has gained prominence, as it is likely
to offer novel solutions to healthcare problems. Some early
success has been achieved in transplanting relatively simple
tissues or organs such as the trachea1 and the bladder.2 These
early accomplishments demonstrate the massive potential of
utilising tissue engineering approaches to restore tissue and organ
function, although much further research is needed, especially for
more complicated organs and tissues.
Stem cells are an exciting cell source, with the potential to be
differentiated into the speciﬁc lineages required for the repair and
restoration of functional tissues. Increased reporting of the
limitations of current methods of using stem cells in tissue
engineering has galvanised research to investigate new methods
of controlling stem cell fate. However, effectively controlling stem
cell proliferation and differentiation, with minimum side effects, is
very challenging.
It has become apparent in recent years that ‘epigenetics’ plays a
massive role in cell fate. ‘Epigenetics’ refers to the post-genetic
modiﬁcations made to DNA sequences and related proteins,
where chemical functional groups such as methyl or acetyl are
transferred onto the DNA or such related protein (e.g., the histone
scaffolds, which DNA is wrapped around). Epigenetic modiﬁca-
tions make no changes to the actual base genomic code, and
epigenetic changes are potentially heritable.3,4 Many diseases,
perhaps most notably cancers, have epigenetics as a key
mediator.5–7
More speciﬁcally, research has discovered that modiﬁcations to
the histone, such as those by histone deacetylation enzymes
(HDACs), affect chromatin structure, and thus stem cell properties
such as potency and differentiation.3,8,9 As such, the epigenetic
make-up of a cell may be crucial for cell-based therapies and
tissue engineering. For example, inhibition of HDACs has been
utilised to improve in vitro expansion methods of human
hematopoietic stem cells,10 to improve bone differentiation of
mesenchymal stem cells (MSCs),11 to enhance the efﬁciency of
induced pluripotent stem cell (iPSC) generation,8 and to increase
the efﬁciency of cellular therapies.12
This review will explore background knowledge of epigenetics,
the structure, and function of HDACs and their inhibitors, highlight
the current uses of and potential of these compounds in cell-
based therapies and tissue engineering and suggest where this
ﬁeld may ﬁnd itself in the future.
EPIGENETICS: POST-GENETIC MODIFICATIONS OF DNA
SEQUENCE
DNA, the set of ‘rules’ which control the cell in its most basic form,
exists as the famous double helix, is packed into tight but ﬂexible
assemblies.13 This ﬂexibility allows constant structural alteration so
that DNA can be utilised in transcription, replication, and repair.14
The 147 base units of DNA wrap around histone proteins, forming
nucleosomes. These can be organised further, with the ever-
changing histone epigenome affecting how compact or how
relaxed these structures are.3
Acetylation is one of the most abundant post-translational
modiﬁcations, and genome-wide analysis of cells has shown that
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acetylation is as frequent as phosphorylation.9,15 The lysine
residues on the histone proteins which DNA wraps around are
especially important sites of acetylation. The deﬁned combination
of these histone modiﬁcations has been termed the ‘histone
code’.16 The histone code can be “read” by proteins, such as
bromodomains, but can also be erased and re-written,17
predominantly by two classiﬁcations of cellular enzymes; histone
deacetylases (HDACs) and histone acetyl transferases (HATs). If
bromodomains are an example of acetylation ‘readers’, HATs are
the ‘writers’, and HDACs are the ‘erasers’.15 HATs mediate the
transfer of acetyl groups onto the lysine residues (histone
acetylation), which results in more open and more transcription-
ally active chromatin structures, as the interactions between the
nucleosomes are altered, and the histone tails are released from
the linker DNA. HDAC enzymes remove those acetyl groups
(histone deacetylation), repressing transcription due to the
formation of a more condensed and transcriptionally silenced
chromatin.3 HDAC inhibitors (HDACis) inhibit the action of HDAC
enzymes, resulting in increased acetylation levels in the cell. This
may affect the chromatin compaction, linked to the potency, or
differentiation potential of stem cells.9 Despite the misleading
name, containing the word ‘histone’, there are a wide range of
non-histone targets of these enzyme.18
THE STRUCTURE AND ACTIVITY OF HDACS
There are 18 human enzymes known to have deacetylation
activity, conventionally numbered 1–18 (e.g., ‘HDAC8’). Based on
molecular phylogenetic analysis of primary structures, their
location in the cell and their homology to yeast enzymes RPD3
and HDA1, these 18 HDACs are grouped into four classes,19 which
can be further subdivided into two categories— classical (classes I,
II and IV) (see Tables 1 and 2 for a summary) and sirtuins (class III).
The activity of the classical HDACs depends on zinc ions (Zn2+),
whereas the sirtuins utilise nicotinamide adenine dinucleotide
(NAD+), a phosphate linked dinucleotide coenzyme. As they have
entirely different mechanisms of action, sirtuins fall outside the
scope of this review; only the classical HDACs are reviewed.20
HDACIS AND SPECIFICITY
HDACis are typically small-molecular compounds which can bind
to and block the action of HDAC enzymes. Some have been
isolated from natural sources, such as Trichostatin A (TSA), or
designed and synthesised in a laboratory, such as MS-275.21
When HDACis bind to, or block, the active site (e.g., the zinc ion)
of HDAC enzymes, they act to block the deacetylation action of
the zinc ion. To date, research has largely focused on non-speciﬁc
HDACi compounds (pan-HDACis); broad spectrum HDACis which
target many of the HDAC isoforms.22 It is widely accepted that
most ﬁrst generation HDACis, such as Vorinostat (suberanilohy-
droxamic acid, SAHA) and Romidepsin23,24 are relatively isoform
unselective.25 However, the ﬁndings can be conﬂicting, for
example, Bradner and co-workers (2010) found some of these
HDACis to be selective for certain HDAC isoforms. Discrepancies
can arise due to a lack of knowledge of HDAC structure and
problems with screening techniques.19 The structure of several
commercially available HDACis can be seen in Fig. 1, showing
Sodium butyrate, Valproic acid (VPA), Trichostatin A (TSA),
Romidepsin, Entinostat (MS-275) and Vorinostat (also known as
Zolinza® or suberoylanilide hydroxamic acid, SAHA).
Whilst some pan-HDACis have proven effective drugs,23,24
research is beginning to focus on isoform-selective inhibitors.
The structural differences between HDAC enzymes mean that
HDACis can be designed to be selective for speciﬁc enzymes. It
has been argued by many that targeting speciﬁc HDACs is key to
the development of future HDAC therapeutics.22,25,26 Table 3
summarises the HDAC class/isoform speciﬁcity of some commonly
used HDACis.
Some HDACis, (perhaps most extensively Vorinostat), have been
explored in clinical trials as cancer treatments. High levels of
deacetylation activity have been linked to tumour pathology and
utilising HDACis to reduce deacetylation activity which allows
cancer suppressing genes to work.27 The anti-cancer action of
HDACis is also due to many other effects of the compounds on
cancer cells, including induction of senescence, activation of
apoptosis and mitotic cell death, growth arrest and anti-
angiogenesis effects.28
Moving on from their applications in oncology, recent publica-
tions have shown the huge potential of using HDACis in other
ﬁelds, such as tissue engineering. The effects of HDACis can be
selective for cancerous cells, even at very low doses, and so the
concentrations optimised to affect tumour cells typically do not
affect normal cells, and their effect on stem/progenitor/normal
somatic cells is often unexplored.24,29,30
THE POTENTIAL OF USING HDACIS IN TISSUE ENGINEERING
HDACis affect many cellular properties, such as the cell cycle,
proliferation rates, gene expression, differentiation potential,
Table 1. Summary of Class I zinc-dependent HDAC isoforms
HDAC Cellular location Tissue distribution Known biological functions
HDAC1 Nucleus193 Ubiquitous194 Cellular proliferation,195,196 and cell cycle regulation and haematopoiesis197,198
DNA damage response,199 cardiac development115,119
Oligodendrocyte, glial cell, synapse and neuronal cell development and
function,146,148,154,155,158,200 regulating Schwann cells156,201
Osteogenic and skeletal muscle development,99,202 cartilage formation43
Modulating T cell response,203 epidermal formation,204 adipogenesis205
HDAC2 Nucleus193 Ubiquitous194 Cell cycle regulation,198 DNA damage response,199 cardiac development115,117
Oligodendrocyte, glial cell, synapse and neuronal cell development and
function,146,148,154,155,158,160,206 regulating Schwann cells151,201
Skeletal muscle development,202 regulating cartilage structure43
epidermal formation,204 adipogenesis205
HDAC3 Nucleus and
cytoplasm193
Ubiquitous194 Cell cycle regulation,207,208 Liver function,38,209 cardiac function,120,121
osteogenic development,99 bone mass and bone formation,67–70,99 including osteoclast
suppression,82 chondroprogenitor differentiation to cartilage68
Brain function162 and proliferation/differentiation of neural cells145,208
hematopoietic stem cell growth10
HDAC8 Nucleus and
cytoplasm193
Ubiquitous194 Craniofacial, skull and bone formation in embryonic development210
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accumulation of reactive oxygen species and changes in cell death
pathways. This is dependent on the cell type and state, choice of
HDACi, and application factors (e.g., exposure time and concen-
tration of inhibitor).28
Work has begun attempting to utilise HDACis for the regenera-
tion of different tissues such as bone,11 cardiac,31 neural/
nervous,32 adipose,33 dental,34,35 liver,36–39 skin,40 pancreas,41
muscle42 and cartilage.43 Also worth noting from a translational
tissue engineering perspective are the reports of HDACis
demonstrating pain relief,44–48 anti-microbial,49 immune-
modulatory50–53 and anti-inﬂammatory properties.7,53–55
Relative to other tissues, a reasonable volume of research has
been undertaken into the link between different HDAC enzymes
and bone, cardiac and neural/nervous tissues, and further, tissue
engineering. Thus, this review article will focus on these three key
areas, looking at the history, current status of in vitro and in vivo
research, and ﬁnally with a nod to future perspectives.
HDACS AND HDACIS IN BONE TISSUE FORMATION AND
REGENERATION
There is still an unmet major clinical need to regenerate bone
tissue for fracture repair and the restoration of bone loss due to
injury, congenital disorders and degenerative diseases. Research-
ers currently typically utilise chemicals such as dexamethasone,
ascorbic acid and phosphate sources,56,57 as well as osteogenic
growth factors such as bone morphogenetic proteins to stimulate
osteogenic differentiation of stem cells toward bone forming
cells.58 These osteoblast-like cells can produce collagen matrix and
modulate matrix mineralisation and maturation.59 However, the
current technologies either have limited efﬁcacy, or adverse side
effects, resulting in a search for additional or alternative
approaches enhancing bone tissue engineering.
History
Osteoblasts and osteoclasts are the two main cell types
responsible for bone formation (osteoblasts), resorption (osteo-
clasts) and remodelling (both). Research into the effect of HDACis
on bone ﬁrst began in the 1990s, when sodium butyrate (NaB) was
found to promote osteoblast bone formation.60
Since then, historically, a large number of studies involving
HDACis have been to investigate their effect on bone densities,
due to initial concerns about the side-effects of HDACis utilised
in cancer therapies on bone tissue and density.61–64 Some
research indicated that SAHA inhibited the growth of bone-
related cell populations, such as human bone marrow stem cells,
whilst also having the potential to increase osteogenic
differentiation in vitro. However, a study found that SAHA did
not affect bone mineral density, and could be a promising tool
for both oncological and tissue engineering applications.65
However, in different animal species, HDACis may affect bone
density in different ways.62
HDAC isoforms and their links with bone
It has been suggested that several HDAC isoforms are linked to
osteoblast activity, in particular, HDAC3 is thought to be closely
linked to bone tissue formation.66–69 HDAC3 interacts with Runx2,
suppressing osteocalcin production and regulating progenitors to
differentiate into osteoblasts.67,70,71 During osteoblast differentia-
tion, HDAC3 activity is reduced, resulting in acetylation of histones
3 and 4. This balance of acetylation can be altered in cells by over-
expressing or under-expressing Nuclear Factor of Activated T Cells
(NFAT) signalling.72 Further linking HDAC3 to bone formation, H3,
as well as H4, acetylation can promote osteocalcin production,
which is essential for bone formation.73 In vivo HDAC3 knockout
reduced osteoblast levels and increased fatty deposits in bone
marrow, seriously compromising skeletal health in mice.68 Another
study found HDAC3 to be essential for bone maintenance during
ageing when knocked down the mouse bone mass was
reduced.69 Similarly, HDAC1 is downregulated during osteoblast
differentiation, making it another potentially interesting bone
linked HDAC enzyme to be targeted with speciﬁc inhibitors to
induce osteoblast differentiation.74 Another class 1 HDAC, HDAC8
is known to suppress osteogenic-related genes expression, and
inhibition of this with VPA promoted osteogenic expression of rat
bone marrow stromal cells.75
Table 2. Summary of Class II and IV zinc-dependent HDAC isoforms
Class HDAC Cellular location Tissue distribution Known biological functions
IIa HDAC4 Nucleus and
cytoplasm193
Brain, heart and skeletal muscle,211,212
prehypertrophic chondrocytes,78 retina,213
neurons214–216
Myoﬁbroblast development,40
chondrocyte hypertrophy and endochondral ossiﬁcation,78
muscular differentiation,212 retinal neuronal function,213
regulation of neuronal activity, cell death and survival214,215
HDAC5 Nucleus and
cytoplasm193
Heart, skeletal muscle and brain,211,217
neurons216
Differentiation of neural stem cells,145 and neuronal activity,216
myocardial and endothelial functions,217
memory function218
HDAC7 Nucleus and
cytoplasm193
Thymus,219 heart, muscle and lung211 In embryonic endothelial cells of developing heart, blood
vessels, mesenchyme and myocardial layers of heart and in lung
tissue,118 role in developing thymocytes,219,220
osteoclast activity,82 inﬂammatory macrophages221
HDAC9 Nucleus and
cytoplasm193
Heart, skeletal muscle and brain211,222 Redundant role in heart development,123
controls genes affected by motor innervation in muscles167
IIb HDAC6 Mainly
Cytoplasm193
Muscle,223 brain,166 heart,224 liver,225
kidneys,226 and teste227
Neuroprotection and neurodegeneration,166 muscular
differentiation,223 arterial modelling,224 tubulin acetylation,
bone mass regulation and immune response modulation,227
involved in cellular response to stress,228,229 and macro-
autophagy,230 platelet activation231
HDAC10 Nucleus and
cytoplasm193
Liver, spleen, kidney,232 skin233 Expressed in the developing brain with neural oligodendrocyte
cells,168 melanin production in the skin,233
promotes autophagy-mediated cell survival in neuroblastoma
cells234
IV HDAC11 Nucleus and
cytoplasm193
Brain,168 heart, skeletal muscle, kidney,235
T cells236
Inﬂuences immune activation versus immune tolerance236
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Jointly HDAC4 and HDAC5 have been found to play a role in
osteoblast differentiation.76,77 HDAC4 also speciﬁcally controls
chondrocyte hypertrophy, which is involved in endochondral
ossiﬁcation during bone formation.78 Moreover, HDAC6 is linked
to the differentiation of MSCs into osteogenic lineages.79
Moving on from osteoblasts, both class I and class II HDAC
enzymes are required for osteoclast differentiation,80 and
Romidepsin, which preferentially inhibits HDAC1 and HDAC2,
inhibits osteoclastogenesis.81 HDAC3 and HDAC7 appear to have
opposite effects: suppression of HDAC7 accelerates osteoclast
differentiation, while suppression of HDAC3 inhibits osteoclast
differentiation.82 Similarly, other researchers have suggested that
HDAC5 and HDAC6 activity will reduce osteoclast differentiation.83
The Wnt signalling pathway is an extensively studied pathway
with a key role in the promotion of osteogenic differentiation of
MSCs. The Wnt pathway cross-talks with pathways such as the
BMP, Notch and Hedgehog pathways, and causes upregulation of
osteogenic mediators Runx2, Dl5x and Osterix, as well as
suppressing PPARγ. It is likely that increased knowledge of how
HDAC enzymes interact with the Wnt pathway will result in
improvements in bone tissue engineering protocols.84
Current status of in vitro research for HDACis in bone tissue
engineering
Although the speciﬁcity of different HDACis is possibly question-
able,19 it is clear that there are obvious differences in effects
between different HDACis on bone-related cells. Reports on the
effects of HDACis on bone cells can be conﬂicting. One study
showed that high levels of HDAC acetylation were found to block
vitamin D stimulation of osteocalcin production, and thus
osteoblast differentiation.85 Lee HW and colleagues (2006) showed
that NaB and TSA increased osteogenic characteristics in rat cell
lines, as well as the upregulation of osteoblast marker genes by
NaB.74 NaB can also promote osteogenic differentiation of
periodontal ligament ﬁbroblasts, and has the added beneﬁt of
modulating inﬂammatory reactions.55 Similarly, TSA, MS-275 and
VPA have been shown to upregulate pre-osteoblast’s osteogenic
gene expression.86 However, other reports suggest that TSA may
not induce osteoblasts maturation.60,66 Another study found that
HDAC2-speciﬁc MS-275 stimulates bone regeneration both in vitro
and in vivo.87,88 Thus, the effects of HDACis on cells are still very
complex and require further study.
As previously highlighted, several publications demonstrate
that HDACis, such as Trichostatin A (TSA) and NaB, inhibit
osteoclast differentiation.60,89,90 In 2007, T Yi and J Baek reported
that TSA could actually cause the death of osteoclasts,91 and Kim
et al. (2012) suggested that HDAC2-speciﬁc inhibitor (MS-275) can
reduce bone absorption.88 These inhibitory effects on osteoclasts
could be utilised to prevent bone loss in inﬂammatory disease.92
Although, contradictorily, it has also been shown that TSA
promoted the expression of RANKL, a ligand integral to osteoclast
formation, function and survival.93 Another HDACi, Largazole was
found to increase the in vitro osteogenic potential of C2C12 cells,
a murine mesenchymal progenitor cell line, the authors believe
this to be due to an increased expression of Runx2 and BMPs.94
MSCs can also be derived from dental pulp and have shown
great potential for tissue engineering particularly for mineralised
tissues such as bone.56 VPA has been shown to improve the
generation of mineral matrix in dental pulp MSCs, as well as
promoting the expression of some osteogenic bone markers such
as osteopontin (OPN) and bone sialoprotein (BSP), albeit with a
decrease in osteocalcin (OC) expression. It was also demonstrated
that shRNA silencing of HDAC2 lead to increased expression of
OPN and BSP, but also the downregulation of OC.95 TSA has also
been shown to promote proliferation and differentiation odonto-
blasts in DPSCs,96 and VPA and TSA have been demonstrated to
increase mineralisation of murine dental pulp-derived cell line
(MDPC-23) cells.35 A recent review of this area has suggested how
bone-related markers and HDACs in hPDLs and DPSCs change
during odonto/osteogenic differentiation.97
It is clear that the choice of HDACi, delivery system and the
length of time that cells are exposed to the HDACis may be vital
for utilising HDACis in bone tissue engineering.98 Several in vitro
studies demonstrate the importance of controlling the length of
time cells that are exposed to the HDACis, leading to researchers
often developing pre-treatment strategies to effect differentiation
in in vitro protocols.99–101
Current status of in vivo research for HDACis in bone tissue
engineering
In the literature, it is not uncommon for in vivo and in vitro studies
to contradict each other. Building on previous work by the
group,101 one of the key ﬁrst studies utilising HDACis in bone
tissue engineering in 2006 reported that the pan-HDACis TSA and
NaB increased osteogenic differentiation of MSCs in vitro and
ex vivo, however, these results could not be recreated in in vivo
conditions.11
In 2010, Hung HM et al. observed an increased osteoblast
differentiation when the α-calcium scaffolds with HDACis TSA and
NaB were placed in rat bone defect models.98 Elsewhere in both
an in vitro and in vivo study, HDACis NaB and VPA have been used
in combination with reduced oxygen environments and adipose-
derived stem cells to achieve the regeneration of bone tissue.100
Backing up their in vitro ﬁndings, Lee et al. (2011) found that when
collagen scaffolds soaked in Largazole solution were implanted in
mouse models, there was improved bone formation.94
O
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Fig. 1 Structures of HDACis commonly found in the literature. Clockwise from top left–Sodium butyrate, Valproic acid, Trichostatin A,
Romidepsin, Entinostat (MS-275) and Vorinostat (SAHA)
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HDACS AND HDACIS IN HEART TISSUE FORMATION AND
REGENERATION
There is a great demand to be able to develop cardiac tissue
engineering and regeneration therapies, as heart disease is a
major killer worldwide.102 It has been suggested that HDAC
proteins are key in cardiac tissue development and repair,103 as
well as the prevention of degenerative cardiac diseases.104 For
example, HDAC activity has been linked to ischaemic injury, which
kills 1 million Americans a year.105 HDACis have potential as drugs
for treatments of cardiac diseases,106–110 as well as in improving
cardiac tissue engineering,31,104,111 although there is a compli-
cated epigenetic landscape to be understood with each indicated
disease associated with the heart.112
History
Cardiac tissue engineering is challenged with selecting a suitable
cell type and obtaining and maintaining enough viable cardio-
myocytes from stem cell populations. Currently, chemicals such as
5-azacytidine, or other methods such as the coculture of MSCs
with mature cardiac muscle cells have been utilised, in an attempt
to control stem cell differentiation.102,113,114 However, these
methods have yielded inconsistent results. Some studies show
that there may be a link between HDAC enzymes and cardiac
differentiation, therefore a potential to utilise HDACis for cardiac
tissue engineering and regeneration.31,104,111 Also, such processes
are very complicated, and research is far from being able to create
functional cardiac tissue.
HDAC isoforms and their links with cardiac tissue
HDAC1 knockout mice die early in embryogenesis at embryonic
day 9.5 due to cardiac defects. HDAC2 deletion leads to survival to
the perinatal stage (shortly after birth), but a subsequent death
due to a variety of cardiac defects. Cardiac tissue-speciﬁc deletion
of HDAC1 or HDAC2 alone resulted in no effect on the heart, but
deletion of both together resulted in cardiac defects.115 Some
reports suggested that activity of the class IIa HDACs (HDAC4, 5, 7
and 9) suppress cardiac hypertrophy (heart wall thickening)116
whereas class I enzymes (HDAC1 and 2) promote hypotrophy.117
Knocking out HDAC7 leads to vascular fatalities in mice.118
During coculture with cardiomyocytes, expression of HDAC1
decreases in bone marrow MSCs. When HDAC1 was knocked down
in these cells, the expression of cardiomyocyte related genes was
then signiﬁcantly increased, further indicating the key role of
HDAC1 in the differentiation down this lineage.119 In both mice
and humans HDAC3 is upregulated during endothelial differentia-
tion, and HDAC7 was upregulated during smooth muscle
differentiation.103 HDAC3 is a regulator of cardiac myocyte
proliferation during cardiac development in mice120 and, also in
mice, is essential to the maintenance of cardiac function and cell
metabolism.121 HDAC4, and HDAC5 in particular are known to be
highly expressed in the heart tissue.122 Individually knocking out
HDAC5 and HDAC9 caused mice to become sensitive to cardiac
stress signals, and knocking down both resulted in severe defects,
suggesting overlapping functions in cardiac tissue development.123
To date, the vast majority of reports studying HDAC isoforms
and heart tissue have been carried out in mouse models; however,
there are obvious differences between the mouse and the
human.124 Different methods of assessing the role of HDAC
knockdown may also affect results.125 Thus, the ﬁndings of these
studies may not represent the true role of HDACis on human heart
disease and development.
Current status of in vitro research for HDACis in cardiac tissue
engineering
TSA is the most studied HDACi in this ﬁeld; along with SAHA, it has
been found to have a strong effect on cardiogenic induction of rat
MSCs when compared with the conventional 5-azacytidine
protocol.111,126 Interestingly, pre-treatment of rat MSCs with 5-
azacytidine enhances the effect of TSA on MSC carcinogenesis,
and improvements were also demonstrated when adding TSA
treatment to the coculture of MSCs and neonatal cardiomyocytes
protocol.111 These researchers suggest that the combination of
HDACis with existing methods could be the future of this research.
TSA has been utilised to stimulate the differentiation of human
adipose-derived stem cells into cardiomyocytes.127 TSA has also
been shown to induce other cardiac cell type differentiation (e.g.,
endothelial and smooth muscle cells) from cardiac side population
stem cells.128 In 2010, Kaichi et al. reported that TSA could reduce
inconsistencies and greatly improve the quality of mouse
cardiomyocytes differentiated from mouse iPSC lines.129 Perhaps
even more interestingly, a short term treatment of human or
mouse embryonic stem cells (ESCs) with TSA can dramatically
promote the differentiation of these ESCs into cardiomyocytes,
and further increase the cardiac function of the resulting
cardiomyocytes.130–132 Furthermore, the use of TSA with mouse
embryonic carcinoma stem cells promoted cardiac development;
however, the upregulation of HDAC4 speciﬁcally decreased
cardiomyogenesis.133
Aside from TSA, Chow and co-workers (2013) used VPA to
promote the maturation of human ESC-derived ventricular
cardiomyocytes. Interestingly, they also suggest that this may be
context dependent and that the developmental stage of the cells
being treated could inﬂuence the outcome.124
Current status of in vivo research for HDACis in cardiac tissue
engineering
There has been limited in vivo validation of the potential of
HDACis in cardiac repair. Lee et al. (2007) proved that VPA and
tributyrin had a positive effect on the remodelling of damage rat
ventricles.12 Further work has shown TSA can improve ventricular
function recovery in a defect model, which was found to be c-kit
signalling dependent.134
Table 3. Summary of the HDAC class/isoform speciﬁcity of commonly used HDACis
HDACi HDACs targeted Notes and references
Sodium butyrate Class I and II Early pan-HDACi237
Valproic acid Class I and II Early pan-HDACi237
Trichostatin A HDAC1, HDAC2, HDAC3, HDAC5, HDAC6 and
HDAC7 (or “Class I and Class II”)
Conﬂicting reports: with a low efﬁcacy to HDAC8 in some studies,238 or as
speciﬁc to HDAC1, HDAC3 and HDAC8,239 or a high level of targeting many
Class I and Class II HDACs19
Romidepsin Class I FDA anticancer agent used to treat various lymphomas237
Entinostat (MS-275) HDAC1, HDAC2 and HDAC3 Widely reported as an isoform-speciﬁc HDACi237,238
Vorinostat (SAHA) HDAC1, HDAC2, HDAC3, HDAC6 and
possibly HDAC7
Speciﬁcity has conﬂicting reports–some report as Class I, II and IV, others just
HDAC1, HDAC2, HDAC3 and HDAC6.19 Multiple reports of just targetting
HDAC7 also reported30
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HDACS AND HDACIS IN THE BRAIN, AND NERVOUS TISSUE
FORMATION AND REGENERATION
The typical mammalian nervous system of the body is made up of
several distinctly different tissue types: the brain and the spinal
cord make up the central nervous system (CNS), separate from the
peripheral nervous system (PNS), which exists to relay information
to and from the CNS.135 Researchers are struggling to develop
effective strategies to heal injuries, or generate tissue from both
the CNS and the PNS. Investigations have shed some light onto key
HDAC enzymes in these tissues and cell populations, often drawing
on the fact HDACis (particularly VPA) have historically actually been
used for the treatment of various neurological diseases.136,137
History
HDACis have been used in the treatment of neurodegenerative
diseases since the 1970s, primarily used to prevent neuron
damage.138 Although VPA earned FDA approval in 1987 for its use
as an anticonvulsant and mood stabiliser,21 it was not until 2001
that histone deacetylation inhibition was identiﬁed as the mode of
action of VPA, resulting in its reclassiﬁcation as a HDACi.139,140
Tissue engineering of these very complicated tissues is a
relatively undeveloped area (especially when compared to the
previously discussed bone and heart tissues), and differentiation
protocols are still being reﬁned and developed. For nervous tissue
engineering, current research mainly focuses on the use of nerve
guide conduits in combination with different growth factors.141
Hu et al. (2012) reported that there might be potential for
epigenetic control to be exploited in nervous tissue engineer-
ing.142 However, the CNS has a much lower regenerative capacity
than the PNS, and current therapies focus mainly on preventing
neurodegeneration, rather than actual full regeneration. Regen-
eration with stem cells and biodegradable and bio-absorbable
materials such as polyethene, collagen, gelatin, and chitosan have
been explored in the brain and spinal cord, but there is a vast
volume of work to be done.143
HDAC isoforms and their links with neural and nervous tissue
HDAC enzymes play a key role in neural cell formation in mouse
ESCs.144 Some HDACs (e.g., HDAC1, HDAC3, HDAC5 and HDAC7)
are highly expressed in neural stem cells but are downregulated
as neuronal cells differentiate, and therefore are thought to play a
role in neuronal differentiation.145,146
More speciﬁcally, HDAC1 induces the differentiation of retinal
progenitor cells and motor neurons in zebraﬁsh development.147
HDAC1 and HDAC2 are linked to neural stem and progenitor cells
and synaptic formation, but only HDAC1 is expressed in fully
differentiated glia.146,148 However, HDAC2 is upregulated in neuronal
differentiation, while HDAC1, HDAC3, HDAC5 and HDAC7 are
downregulated.149–153 In mice, HDAC1 and HDAC2 activity are
required for oligodendrocyte differentiation, as well as Schwann cell
development.154,155 They are also regulators of myelination in the
peripheral nervous system.156 However, other researchers report
that, in general, HDAC activity inhibits the differentiation of
oligodendrocytes to neurons.157 HDAC2 activity may be related to
the differentiation of neural progenitors,151,153 and can inhibit
astrocyte differentiation.154 Knockout of both HDAC1 and HDAC2 in
mice neuronal precursor cells leads to cell abnormalities, disorga-
nisation and postnatal mouse fatality.158 Individually knocking down
HDAC1 or HDAC2 also affects neuronal development of mice.159,160
HDAC3 is key to neuronal survival, control of apoptosis, and is
linked to neural disease,161 and memory function.162 HDAC3,
together with HDAC1 and HDAC2, has been linked to cortical cell
differentiation.154 HDAC8 is not found to be expressed in normal
cells from the central or peripheral nervous system, but is linked to
related cancers, notably childhood neuroblastoma, so could be a
promising target in this ﬁeld.26,163
Caution should be exercised when exploring HDACis in this
ﬁeld, as it has been demonstrated that targeting class I HDACs
with inhibitors in human oligodendrocyte progenitor cells leads to
a reduction in progenitor recruitment via proliferation arrest, and
inhibition of differentiation into oligodendrocytes. Consequently,
Conway and co-workers emphasis that it is also important to
realise that there are subtle differences between species in
regulation of HDAC activity.157
Of the class II HDACs, HDAC4 is key, to neuronal activity, and
highly expressed in the brain, in neurodegenerative disorders, and
HDAC4 activity is thought to provide the neurons protection from
cell death by preventing abortive cell cycle progression.164
HDAC5, HDAC6 and HDAC7 are all linked to neural diseases, such
as Huntingdon’s disease, protein aggregated diseases and to
neural mitochondrial-related diseases respectively.163 HDAC5
mediated pathways are linked to early-stage neural cell fate.165
HDAC6 has a complicated role in these systems with both a
neuroprotective and neurodegenerative role.166 HDAC9 is highly
expressed in the brain and is proposed to be important in the
formation of nerve synapses.167
Interestingly, the only class IV HDAC, HDAC11, is barely
expressed in precursors to neural cells, but largely features in
mature neurons, and therefore is thought to be key to postnatal
development of neurons.168
Current status of in vitro research for HDACis in neural and
nervous tissue engineering
Neural stem cells were ﬁrst isolated and reported in the early
90s,169,170 and subsequently several related other distinct cell
populations have since been discovered.171,172 Due to the
importance of different HDAC isoforms in neuronal and nervous
tissue development, the use of speciﬁc HDACis could be an
especially promising approach for improving the current
approaches in tissue engineering. However, so far, only limited
studies into the effects of HDACis on relevant neuronal cells have
been undertaken.
As Valproic acid (VPA) obtained FDA approval for treating
neurological diseases in the 1980s, there has been a relatively
large volume of work on the effects of VPA on cells of these
systems.173 VPA can induce neuronal differentiation of adult rat
hippocampal neural progenitor cells whilst inhibiting glial cell
differentiation; favouring neuronal differentiation.32 VPA can alter
cell function and microglial phenotype of fully developed human
glial cells, although it does not result in apoptosis as shown in
rodent cells.174 In a different study, VPA was shown to enhance rat
cerebral cortex neural progenitor cell neural differentiation both
in vitro and in vivo.175 Moreover, VPA has been shown to control
oligodendrocyte progenitor differentiation.150 VPA induces pro-
neural factors in rat cells, speciﬁcally it has been shown that early
stage progenitor cells are more sensitive to the effects of HDAC
inhibition, which is thought to be linked to H4 acetylation.176
Juliandi and co-workers (2012) reported that VPA treatment
enhanced the differentiation of mouse-derived ESCs into neuronal
lineage layers.177 However, VPA has also been demonstrated to
inhibit proliferation, cell “stemness” and the ability to form
neurospheres of mice adult subventricular zone cells, a separate
neural cell population.178 Finally, it has been demonstrated that
VPA increases axonal growth of neurons in vitro.179
Similar to VPA, TSA has also been utilised to induce mouse
neural cells (in minimal supplement media) to express some of the
properties of fully functioning neurons.180 In a separate study,
Siebzehnrubl et al. (2007) found that the HDACis MS-275, M344
and SAHA induced the neuronal differentiation of mouse forebrain
precursor cells.181 Also, HDACi treatment has been combined with
extrinsic transcription factors to promote mouse neural cells to
differentiate into dopaminergic neurons.182 When treated with
HDACis, mouse cells showed increased plasticity, reversed lineage
commitment and upregulation of 13 genes associated with neural
stem cell states, e.g., Sox2.183 Interestingly, HDAC1 and HDAC2
inhibition can be detrimental to oligodendrocyte
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differentiation.157,183 However, in comparison, HES5 (a notch
regulator) was not upregulated in human cells. Thus, once again in
this ﬁeld, it is important to note that not all animal cell models
may be directly translatable into human models.157
Current status of in vivo research for HDACis in nervous tissue
engineering
Unsurprisingly, given the limited number of in vitro studies, there
is only a handful of in vivo studies speciﬁcally related to tissue
engineering and/or regeneration. An in vivo model of the
aforementioned in vitro study demonstrated that VPA regulates
differentiation and proliferation of rat cerebral cortex neural
progenitor cells in the cerebral cortex of developing rat
embryos.175 VPA has also been proven to reduce cell apoptosis
and increase locomotion recovery in a rat spinal cord injury
model.184 VPA has also been shown to increase the differentiation
of NSCs into neurons, not glial cells, along with improved limb
function, in mouse spinal cord injury models.185
A BRIEF DISCUSSION OF THE ROLE OF HDACS AND HDACIS IN
SKELETAL MUSCLE
Skeletal muscle tissue formation is also regulated by signalling
pathways such as Wnt, BMP and the Class II HDACs (HDAC4,
HDAC5, HDAC7 and HDAC9) are highly expressed in skeletal
muscle. HDACs play a key role in the epigenetic regulation of
embryonic myogenesis and adult muscle regeneration.186 For
example Class II HDACs are known to directly bind myocyte
enhancer factor-2 (MEF2) and consequently repress expression of
MEF2-dependent genes.187,188 HDAC enzymes and their signalling
pathways play a key role in regulating myocyte differentiation and
remodelling of muscle tissue.187,189 HDAC4, in particular, is
necessary for maintaining skeletal muscle homoeostasis and
function. And it has been identiﬁed as a potential target for
treatment of skeletal muscle disorders such as cancer cachexia,
amyotrophic lateral sclerosis (ALS) or muscular dystrophy.190
SUMMARY
In these three key tissue areas, it has been demonstrated HDACis
could be very useful tools to improve tissue engineering
strategies. Since bone tissue engineering has found early success
with studies combining MSCs with HDACis,11,100,101 there is
potential to translate this research into clinical settings. Similarly,
for cardiac tissue engineering, the many studies involving TSA is a
strong beginning for this ﬁeld,108 and when isoform-speciﬁc
strategies begin, HDAC4 in particular has proven a potentially
interesting target for cardiac tissue engineering.122 Regarding
neural tissue engineering, most of the studies have explored the
use of VPA, which is considered a pan-HDACi. Therefore, it is
believed that selective isoform targeting may lead to improve-
ments in this ﬁeld.163,191
Presently, researchers aim to combine suitable cells (e.g., MSCs)
with scaffolds, chemical cues (e.g., growth factors) and environ-
mental stimuli (e.g., mechanical stimulation) to general functional
tissue, such as new nerves, bone and other muscular-skeletal
tissues in dentistry and/or orthopaedics. This can be carried out
in vitro before being implanted/transplanted in vivo, where the
naturally occurring cells can populate the scaffold and chemical
cues aid the growth of the targeted tissues. Therefore, HDACis
could be utilised as the chemical cues to improve the efﬁcacy of
current tissue engineering techniques.
FUTURE PERSPECTIVES
There has been some early success stories utilising HDACis in
tissue engineering, but looking to the future, the rise of isoform-
speciﬁc HDACis may lead this research to new heights. There is
still plenty to be said for the classical HDACis; however, the
connection between tissues and speciﬁc HDAC isoforms should
lead to more examples of targeted tissue engineering scenarios.
The current limitations of the technologies must be considered:
● a lack of understanding of the pathways HDAC enzymes
themselves are involved in, and the effects of these enzymes
on cellular properties and behaviour;
● a fundamental lack of knowledge of the function of individual
HDAC enzymes, in different cell/tissue types;
● the mechanism of action of many HDACis, i.e., how pan-
HDACi’s function, what HDAC isoforms each actually inhibits,
and therefore their true mechanisms of action;
● full optimisation of the desired concentration and treatment
period of each HDACi on individual cells, to give the best
outcome; and
● the need for extensive in vivo testing in clinically relevant
animal models, with particular attention to the side effects,
before the translation of any HDACis for clinical therapies in
this area.
CONCLUSION
In conclusion, the ﬁeld of HDACis in tissue engineering is still in its
infancy compared with cancer research where at least 4 HDACis
have achieved clinical approval, with many others in late-stage
clinical trials.192 As demonstrated herein, easily synthesised small-
molecular compounds in low concentrations could massively
improve the efﬁcacy of stem cell therapies and tissue engineering,
potentially without the risks associated with genome altering
therapies. As discussed at length in this review, there is a potential
paradigm shift in this ﬁeld with the rise of isoform-speciﬁc HDACis.
As more regulatory barriers are cut, due to increased clinical
approval of HDACis, the potential to translate these compounds in
other ﬁled such as in tissue engineering has been increased.
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